Gary A Piazza

Summary

Affiliation: Southern Research Institute
Country: USA

Publications

  1. ncbi A novel sulindac derivative that does not inhibit cyclooxygenases but potently inhibits colon tumor cell growth and induces apoptosis with antitumor activity
    Gary A Piazza
    Drug Discovery and Development Divisions, Southern Research Institute, Birmingham, Alabama 35205, USA
    Cancer Prev Res (Phila) 2:572-80. 2009
  2. ncbi A novel sulindac derivative that potently suppresses colon tumor cell growth by inhibiting cGMP phosphodiesterase and β-catenin transcriptional activity
    Jason D Whitt
    Department of Pharmacology, The University of Alabama at Birmingham, Birmingham, AL, USA
    Cancer Prev Res (Phila) 5:822-33. 2012
  3. ncbi Inhibition of PDE5 by sulindac sulfide selectively induces apoptosis and attenuates oncogenic Wnt/β-catenin-mediated transcription in human breast tumor cells
    Heather N Tinsley
    Drug Discovery Division, Southern Research Institute, Birmingham, Alabama, USA
    Cancer Prev Res (Phila) 4:1275-84. 2011
  4. ncbi Sulindac sulfide selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G
    Heather N Tinsley
    Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL 35205, USA
    Mol Cancer Ther 8:3331-40. 2009
  5. ncbi Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt/β-catenin pathway
    Wenyan Lu
    Drug Discovery Division, Department of Biochemistry and Molecular Biology, Southern Research Institute, Birmingham, Alabama, United States of America
    PLoS ONE 6:e29290. 2011
  6. ncbi Suppression of Wnt/beta-catenin signaling inhibits prostate cancer cell proliferation
    Wenyan Lu
    Department of Biochemistry, Drug Discovery Division, Southern Research Institute, 2000 Ninth Avenue South, Birmingham, AL 35255 5305, United States
    Eur J Pharmacol 602:8-14. 2009

Research Grants

  1. cGMP Phosphodiesterase, a Novel Chemoprevention Target
    Gary Piazza; Fiscal Year: 2005
  2. Novel Sulindac Derivatives for Colon Cancer Chemoprevention
    Robert C Reynolds; Fiscal Year: 2010
  3. A Novel HTS Cell-Based Assay For Cyclic GMP
    Gary Piazza; Fiscal Year: 2007
  4. A novel sulindac derivative for colon cancer chemoprevention
    Gary Piazza; Fiscal Year: 2007
  5. Development of a novel sulindac amide for colorectal cancer chemoprevention
    Gary A Piazza; Fiscal Year: 2010

Collaborators

Detail Information

Publications6

  1. ncbi A novel sulindac derivative that does not inhibit cyclooxygenases but potently inhibits colon tumor cell growth and induces apoptosis with antitumor activity
    Gary A Piazza
    Drug Discovery and Development Divisions, Southern Research Institute, Birmingham, Alabama 35205, USA
    Cancer Prev Res (Phila) 2:572-80. 2009
    ..These results indicate that SSA has potential safety and efficacy advantages for colon cancer chemoprevention as well as utility for treating malignant disease if combined with chemotherapy...
  2. ncbi A novel sulindac derivative that potently suppresses colon tumor cell growth by inhibiting cGMP phosphodiesterase and β-catenin transcriptional activity
    Jason D Whitt
    Department of Pharmacology, The University of Alabama at Birmingham, Birmingham, AL, USA
    Cancer Prev Res (Phila) 5:822-33. 2012
    ..We conclude that PDE5 and possibly other cGMP degrading isozymes can be targeted to develop safer and more efficacious NSAID derivatives for colorectal cancer chemoprevention...
  3. ncbi Inhibition of PDE5 by sulindac sulfide selectively induces apoptosis and attenuates oncogenic Wnt/β-catenin-mediated transcription in human breast tumor cells
    Heather N Tinsley
    Drug Discovery Division, Southern Research Institute, Birmingham, Alabama, USA
    Cancer Prev Res (Phila) 4:1275-84. 2011
    ..We conclude that PDE5 represents a novel molecular target for the discovery of safer and more efficacious drugs for breast cancer chemoprevention...
  4. ncbi Sulindac sulfide selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G
    Heather N Tinsley
    Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL 35205, USA
    Mol Cancer Ther 8:3331-40. 2009
    ..These data suggest that PDE5 inhibition is responsible for the breast tumor cell growth-inhibitory and apoptosis-inducing activity of SS and may contribute to the chemopreventive properties of sulindac...
  5. ncbi Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt/β-catenin pathway
    Wenyan Lu
    Drug Discovery Division, Department of Biochemistry and Molecular Biology, Southern Research Institute, Birmingham, Alabama, United States of America
    PLoS ONE 6:e29290. 2011
    ....
  6. ncbi Suppression of Wnt/beta-catenin signaling inhibits prostate cancer cell proliferation
    Wenyan Lu
    Department of Biochemistry, Drug Discovery Division, Southern Research Institute, 2000 Ninth Avenue South, Birmingham, AL 35255 5305, United States
    Eur J Pharmacol 602:8-14. 2009
    ..Together, these results suggest that small molecules that inhibit Wnt/beta-catenin signaling have therapeutic potential for the prevention or treatment of prostate cancer...

Research Grants10

  1. cGMP Phosphodiesterase, a Novel Chemoprevention Target
    Gary Piazza; Fiscal Year: 2005
    ..Finally, cGMP and cAMP levels will be measured in tumors and plasma samples from this study to determine if PDE inhibition occurs in vivo and the utility of cyclic nucleotides as biomarkers. ..
  2. Novel Sulindac Derivatives for Colon Cancer Chemoprevention
    Robert C Reynolds; Fiscal Year: 2010
    ..This multidisciplinary research proposal may lead to a novel strategy for colon cancer chemoprevention. ..
  3. A Novel HTS Cell-Based Assay For Cyclic GMP
    Gary Piazza; Fiscal Year: 2007
    ..Towards this goal, we propose to develop an innovative cell-based assay involving a fluorescence cGMP biosensor for high throughput screening. ..
  4. A novel sulindac derivative for colon cancer chemoprevention
    Gary Piazza; Fiscal Year: 2007
    ....
  5. Development of a novel sulindac amide for colorectal cancer chemoprevention
    Gary A Piazza; Fiscal Year: 2010
    ..These studies are anticipated to result in a new drug candidate for clinical trials involving patients with familial or sporadic adenomatous polyposis who are at high risk of developing colorectal cancer. ..